Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
Prognostic models of drug-induced neutralizing antibody formation in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis treated with TNF-α blockersockers [PDF]
Krasimir Kraev +8 more
openalex +1 more source
IMMUNITY IN DIABETES. III. RELATION OF TISSUE GLYCOGEN AND BLOOD CHEMISTRY TO BACTERIAL DISSEMINATION, ANTIBODY FORMATION AND SURVIVAL AFTER INFECTION IN DIABETES [PDF]
, 1940 Russell S. Richardson
openalex +1 more source
ATF4‐mediated stress response as a therapeutic vulnerability in chordoma
Molecular Oncology, EarlyView.We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone +11 more
wiley +1 more source
Frequency of Red Cell Alloantibodies in Pregnant Women of North West Pakistan
Journal of Islamic International Medical College, 2017 Objective: The objective of this study was to determine the frequency of red cell alloantibodies in pregnant women of North West Pakistan. Study Design: It was a descriptive study. Place and Duration of Study.
Maria Shafiq , Ayesha Noor , Amer Siddiq
doaj
Antibody Formation in Myelomatosis [PDF]
Journal of Clinical Pathology, 1953 openaire +2 more sources
Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase
, 2015 Jiten Vora +5 more
openalex +1 more source
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. [PDF]
J Intern Med, 2022 Brun MK +14 more
europepmc +1 more source
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source